BMC Med:HIV患者脑膜炎球菌感染风险更大

2015-12-23 MedSci MedSci原创

近期有研究表明,HIV感染是侵袭性脑膜炎球菌(IMD)感染的潜在危险因素,对HIV感染个体注射脑膜炎球菌疫苗或可降低这种罕见但致命的风险。不过在工业化国家英国,并没有认为HIV是IMD的风险因素。研究者对英格兰2011-2013年全国数据进行了分析研究,探究IMD发生率与HIV的联系。研究数据显示,HIV患者中IMD发生率为6.6/100,000,非HIV人群IMD发生率为1.5/100,000。

近期有研究表明,HIV感染是侵袭性脑膜炎球菌(IMD)感染的潜在危险因素,对HIV感染个体注射脑膜炎球菌疫苗或可降低这种罕见但致命的风险。不过在工业化国家英国,并没有认为HIV是IMD的风险因素。

研究者对英格兰2011-2013年全国数据进行了分析研究,探究IMD发生率与HIV的联系。

研究数据显示,HIV患者中IMD发生率为6.6/100,000,非HIV人群IMD发生率为1.5/100,000。两组比较RR=4.5 (95 % CI, 2.7-7.5)。有一例16-64岁成年人中IMD病例,与非HIV人群相比,其IMD风险为22.7倍 (95 % CI, 12.4-41.6; P <0.001)。不同年龄IMD风险不同。HIV阳性的儿童和青少年B族脑膜炎球菌感染风险更高,成年人则是C、W、Y感染风险更高。绝大部分HIV患者来自非洲,因同性性行为感染HIV,诊断为IMD时被告知HIV阳性且接受抗病毒治疗。最常见的临床表现是败血症,虽然通常会进入ICU治疗,但没有发现IMD死亡病例。

研究结果表明,HIV阳性的儿童和成年人,发生IMD风险大大增加,对HIV阳性患者使用脑膜炎球菌疫苗或可降低该风险。

原始出处:

Simmons RD, Kirwan P,et al.Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study.BMC Med. 2015 Dec 9;13(1):297.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003345, encodeId=f12f200334547, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon May 30 01:28:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974657, encodeId=148119e4657ce, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Nov 29 04:28:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54685, encodeId=7224546855f, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50154, encodeId=a1f850154fe, content=治疗困难, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50155, encodeId=03265015595, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606776, encodeId=3fe61606e7677, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 25 03:28:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003345, encodeId=f12f200334547, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon May 30 01:28:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974657, encodeId=148119e4657ce, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Nov 29 04:28:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54685, encodeId=7224546855f, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50154, encodeId=a1f850154fe, content=治疗困难, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50155, encodeId=03265015595, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606776, encodeId=3fe61606e7677, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 25 03:28:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003345, encodeId=f12f200334547, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon May 30 01:28:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974657, encodeId=148119e4657ce, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Nov 29 04:28:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54685, encodeId=7224546855f, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50154, encodeId=a1f850154fe, content=治疗困难, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50155, encodeId=03265015595, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606776, encodeId=3fe61606e7677, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 25 03:28:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2016-01-08 andruhn

    好东西,值得分享,学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2003345, encodeId=f12f200334547, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon May 30 01:28:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974657, encodeId=148119e4657ce, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Nov 29 04:28:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54685, encodeId=7224546855f, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50154, encodeId=a1f850154fe, content=治疗困难, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50155, encodeId=03265015595, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606776, encodeId=3fe61606e7677, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 25 03:28:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2015-12-29 xyfg98

    治疗困难

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2003345, encodeId=f12f200334547, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon May 30 01:28:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974657, encodeId=148119e4657ce, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Nov 29 04:28:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54685, encodeId=7224546855f, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50154, encodeId=a1f850154fe, content=治疗困难, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50155, encodeId=03265015595, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606776, encodeId=3fe61606e7677, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 25 03:28:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2015-12-29 xyfg98

    值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2003345, encodeId=f12f200334547, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon May 30 01:28:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974657, encodeId=148119e4657ce, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Nov 29 04:28:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54685, encodeId=7224546855f, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50154, encodeId=a1f850154fe, content=治疗困难, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50155, encodeId=03265015595, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 12:38:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606776, encodeId=3fe61606e7677, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 25 03:28:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]

相关资讯

Lancet HIV:服用阿巴卡韦治疗青少年艾滋病患者有何毒副反应?

关注抗逆转录病毒疗法中青少年出现的毒副反应是至关重要的。针对服用阿巴卡韦(一种广泛使用的抗逆转录病毒药物)后儿童和青少年出现的不良反应和副作用,研究人员进行了一项系统回顾和荟萃分析。

JAMA Pediatrics:男男性行为,更易传播HIV

艾滋病毒传播在男男性行为(MSM)呈增长趋势,在异性恋人群中则保持相对稳定。年轻的男男同性恋者(YMSM)一般年龄范围为13-29岁,极易受艾滋病毒感染,超过25%的新发感染发生于美国,超过70%的艾滋病毒新发感染者为年轻人。

发生HIV职业暴露后,怎么办 ?

HIV职业暴露是HIV感染者及病人的血液或体液,(阴道分泌物、羊水)及含有HIV的实验室样本,污染了医务人员破损的皮肤、黏膜或被针刺伤或利器割伤。由于艾滋病的无症状感染期很长,HIV感染者从外表无法辨别,却具有传染性;另外,因艾滋病无特异的临床表现,病人常到各科(内科、皮肤科、神经科、口腔科等)就医,就诊时不易及时做出正确诊断,所以,医务人员在临床工作中面对更多的是潜在的传染源。所以非常有必要掌握

2015年关于HIV/AIDS的10大事实

尽管目前对HIV/AIDS的认识等有重大进展,但是HIV/AIDS依旧是全球范围内重大公共卫生挑战,尤其是低中收入国家;撒哈拉以南非洲女性风险尤其高。自1984年起,每年的12月1日作为世界艾滋病日,这一天将举办各种宣传和普及预防艾滋病的知识有关活动,意在团结大众抵抗HIV,支持HIV感染人群,纪念已故人群。9月联合国成员达成一致协议:将于2030年终结AIDS的流行。虽然目标宏伟,但根据WHO、

艾滋病日过去了,避孕套的研究与创新还在继续

昨日12月1日是世界艾滋病日。1995年美国总统将艾滋病日定于12月1日,这个特殊有具有重大意义的日子便引起的公众的注意,研究人员希望通过这一天以致力于提高公众的安全意识和疾病认知。

讲座:巴尔的摩的免疫工程疗法 让人类最终战胜HIV

戴维·巴尔的摩(英语:David Baltimore,1938年3月7日-),美国生物学家,1975年诺贝尔生理学或医学奖获得者之一,加州理工学院生物学教授,美国科学促进会会长。   近30年来,David Baltimore作为麻省理工学院的一名教员。在他早期对脊髓灰质炎病毒的研究中,于1970他发现了肿瘤病毒的逆转录酶,从而为病毒从RNA到DNA的转化过程,提供了强有力的证据